Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• The development of effective and safe cancer therapies is a critical medical need.
• Oncolytic viruses (OVs) represent a promising therapeutic strategy, selectively targeting tumor cells and eliciting anti-cancer immune responses.
• Herpes Simplex Virus 1 (HSV-1) is a well-studied OV candidate due to its genetic capacity and safety profile.

Purpose of the Study:

• To review Herpes Simplex Virus 1 (HSV-1) as an oncolytic virus (OV) candidate.
• To describe the genomic organization of Talimogene laherparevec (T-VEC), an approved HSV-1 derived OV.
• To compare T-VEC with other HSV-1 OV variants in clinical development and discuss future directions.

Main Methods:

• Literature review of HSV-1 based oncolytic viruses.
• Analysis of T-VEC's genomic structure and clinical status.
• Comparative assessment of T-VEC against other HSV-1 OV variants.

Main Results:

• Talimogene laherparevec (T-VEC) is the first and only oncolytic virus therapy approved by the FDA.
• HSV-1 offers a robust platform for OV development due to its infectivity and large genome.
• T-VEC has demonstrated potential but also presents limitations compared to other emerging HSV-1 OV variants.

Conclusions:

• HSV-1 based oncolytic viruses, exemplified by T-VEC, hold significant therapeutic potential in oncology.
• Understanding the advantages and limitations of T-VEC is crucial for optimizing its clinical application.
• Future research should explore novel strategies to enhance the efficacy and broaden the application of HSV-1 OVs in cancer treatment.